How Novus Can Take Advantage of the Proposed Federal Cannabis Research Protections Bill

About this update from Novus Acquisition & Development Corp.

[Miami, Florida] — April 22, 2026 —Novus Acquisition & Development Corp. (OTC: NDEV), a national provider of supplemental health insurance plans, operating as Novus Cannabis MedPlan, is a pioneer in offering cannabis coverage for both recreational and medicinal users. The company, which is focused on cannabinoid-based wellness, precision biotech, InsurTech, and health plans, views the introduction of the federal "Cannabis Research Protections" bill as a crucial catalyst for sustainable growth. This strategic update to shareholders and the investment community highlights that the landmark legislation—which aims to shield researchers, academic institutions, and clinical participants from federal prosecution—validates and accelerates Novus's long-term business model. For years, the cannabis industry has operated under a "Catch-22": federal regulators demanded clinical data to justify policy shifts, yet federal restrictions prevented the very research needed to produce that data. The proposed bill effectively breaks this cycle. A Pivot Toward Institutional-Grade Validation The core of the Novus business model has always been the transition from anecdotal consumer health plans to scientifically validated wellness solutions. Until now, major research universities and healthcare providers have remained on the sidelines due to the risk of losing federal funding. "This bill is the 'Green Light' we have been preparing for since our inception," said Frank Labrozzi, CEO of Novus. "By removing the threat of federal interference, this legislation allows Novus to enter formal partnerships with Tier-1 research institutions. It moves our health plan to a more 'compliant' to 'clinically proven,' which is the single most important factor in unlocking institutional capital and mainstream consumer trust." Strategic Impact on the Novus Business Model The Novus business model is uniquely positioned to benefit from these protections in three distinct ways: Intellectual Property (IP) Moat Construction: Novus plans to use the robust intellectual property (IP) portfolio generated from these third-party clinical trials to create a competitive "moat." This data, made possible by federal research protections, will accelerate the development of better-targeted health plans and differentiate Novus from mere "commodity" cannabis producers. Pathway to Insurance and Healthcare Integration: The primary barrier to insurance reimbursement for cannabinoid therapies has been the lack of federally recognized clinical data. By facilitating protected research, this bill clears the path for Novus to pursue medical-grade certifications, potentially opening revenue streams via healthcare provider networks and insurance coverage. Operational De-Risking: For investors, the "cannabis risk premium" has historically been tied to federal uncertainty. This bill serves as a de-risking event, signaling a permanent federal shift toward a science-first regulatory framework. This is expected to lower the cost of capital and increase Novus's attractiveness to institutional portfolios and major exchange listings. Data-Driven Competitive Advantage While much of the industry has focused on retail expansion, Novus has invested heavily in standardized delivery systems and high-fidelity formulations. The new federal framework allows Novus to prove the efficacy of these systems through rigorous, peer-reviewed studies without the looming shadow of the Controlled Substances Act interfering with university partners. "We are not just selling a health plan; we are building a research-backed platform," added Frank Labrozzi. "This bill allows us to treat our actuarial department like a traditional biotech firm, striving to achieve the best profit outcomes in cannabis meds. For our investors, this means we are no longer just participating in a trending market—we are leading the professionalization of a new category of medicine." About Novus Further Research: Financial Filings:  Click Here Quote: Click Here Investor's Page : Click Here  Novus (NDEV) operates through its wholly-owned subsidiary, WCIG Insurance Services, Inc. The company provides health plans as a health insurance carrier in states with legal medical marijuana programs. Novus' business model is based on receiving insurance premiums and does not involve the cultivation, distribution, or sale of cannabis or cannabis-related products. Forward-Looking Statements This release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Dilution, if any, would be for the purposes of management taking stock in lieu of cash salary. Novus disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Additionally, this press release that is not statements of historical fact may be considered to be forward-looking statements. Written words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future.     Investor Contact Information Investor Website 855-228-7355  Email: [email protected]

View stock analysis, news, and events for Novus Acquisition & Development Corp.